Biogennix Launches Agilon Surgical Matrix

Osteobiologics Leader Enters Wound Care Space with Cutting Edge Solution

IRVINE, Calif.--(BUSINESS WIRE)-- Biogennix, an osteobiologics company specializing in innovative healing solutions for surgical procedures, has announced the launch of its new Agilon Surgical Matrix wound care product.

Agilon Surgical Matrix is a wound care solution derived from 100% bovine Type 1 collagen. Upon contact with a new or open wound, whether surgically or naturally occurring, Agilon Surgical Matrix transforms into a gel, enveloping the entire wound area. This coverage maintains a low pH wound environment that aids in the formation of tissue and epithelialization, which is conducive to successful wound healing.

Backed by in vitro performance data, Agilon Surgical Matrix demonstrates wide-ranging antimicrobial properties, offering added protection against infections. The product’s versatility extends to various surgical applications, serving as an alternative to close-suction drains, blood vessel ligation, or surgical site immobilization in preventing postoperative seromas.

With its sterile, single-use packaging, Agilon Surgical Matrix provides a safe and effective option for healthcare professionals and patients.

“Based on the enthusiastic feedback we’ve received from surgeons, we anticipate Agilon Surgical Matrix to be a significant addition to our product offering that will open the doors to a wide variety of indications,” said Greg Yocum, Biogennix’s VP of Business Development. “Because Agilon Surgical Matrix is purified low pH, bovine Type 1 collagen, it represents a significant advancement in surgical and post-operative care management, offering a myriad of benefits – including antibacterial properties – which enhance patient outcomes and facilitate healing. This product also opens the door for Biogennix to participate in the wound care market.”

Agilon Surgical Matrix can be used in the management of partial and full thickness wounds, pressure (stage I – IV) and venous ulcers, ulcers caused by mixed vascular etiologies, venous stasis and diabetic ulcers, first and second degree burns, cuts, abrasions, and surgical wounds.

Surgical areas include orthopedic, podiatry, cardiovascular, abdominal, neurologic, plastic/breast reconstruction, general, OB/GYN, trauma, vascular, burns, and ulcers.

About Biogennix:

Biogennix is a pioneering osteobiologics company based in Irvine, California, committed to developing, manufacturing, and distributing advanced products for surgical procedures. Its focus on innovation, quality, and customer satisfaction continues to set it apart as a leader in the medical device industry.

“Agilon” is a registered trademark of Biogennix.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240724040098/en/

Paul Williams
(310) 569-0023
[email protected]

Source: Biogennix

You May Also Be Interested In

• Provation Expands Global Footprint with Launch of Provation® Apex in Australia and New Zealand
• Waton Financial to Bring MoTA's Multi-Agent Investment Platform to Individual Investors
• Grupo Aeroportuario Del Pacifico Announces Results for the Second Quarter of 2026